The organization **PSG** primarily refers to **Pharmaceutical Strategies Group**, a leading strategic consultancy specializing in drug cost management and benefit design within the healthcare and pharmaceutical sectors. PSG partners with employers, health plans, and labor groups to provide data-driven insights, intelligence, and technology solutions that help clients navigate the complex challenges of managing drug benefits, including specialty and non-specialty drugs[6][7]. Founded as a specialized consultancy, PSG has grown its reputation by consistently delivering actionable research and trend analysis. Its annual reports, such as the 2025 Drug Benefit Design Report and Trends in Specialty Drug Benefits Report, are highly regarded in the industry for providing comprehensive data on drug benefit trends, cost management strategies, and payer behaviors. These reports shed light on critical issues like drug cost containment, utilization management, and emerging therapies such as cell and gene treatments, helping clients make informed decisions amid rising healthcare costs[6][7]. PSG's key achievements include enabling billions of dollars in drug cost savings for its clients annually through its strategic guidance and industry-leading intelligence. The company’s influence extends across multiple stakeholders in healthcare, including employers, unions, and health plans, making it a pivotal player in shaping drug benefit policies and practices in the U.S. and beyond[6]. Currently, PSG remains at the forefront of pharmaceutical consulting, continuously updating its research to reflect the evolving landscape of drug benefit design, including trends like pharmacy benefit manager (PBM) unbundling and coverage decisions for expensive therapies such as GLP-1 drugs. This proactive approach ensures that PSG clients stay ahead of regulatory, financial, and clinical challenges[6][7]. Notable aspects of PSG include its role as a relentless advocate for clients in managing drug costs and its commitment to delivering transparent, data-backed insights that influence both policy and business decisions in healthcare benefits management. PSG’s work directly impacts how organizations optimize drug spending while maintaining quality patient care in an increasingly complex pharmaceutical environment[6].